Corcept Therapeutics has submitted an application to the European Medicines Agency seeking approval of relacorilant for the treatment of…
Articles by Lindsey Shapiro, PhD
Glitches in a cellular process that are often seen in neurodegenerative diseases and dementia may also play a role in…
A cell-based immunotherapy that’s designed to overcome the defense mechanisms that help ovarian cancer evade treatment was highly effective at…
The European Union (EU) expanded its approval of Sarclisa (isatuximab-irfc), making it available to newly diagnosed adults with multiple…
A vaccine therapy called ELI-002 2P led to anti-cancer immune responses in a Phase 1 trial and showed potential for…
The number of uterine cancer cases and related deaths — the disease’s incidence and mortality rates — in the U.S.
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to MB-101, a CAR T-cell therapy being developed…
Corcept Therapeutics has asked the U.S. Food and Drug Administration (FDA) to approve relacorilant, to be used in combination…
The first patient has been dosed in a Phase 3 trial testing the investigational therapy BAT8006 in people with platinum-resistant…
A European Medicines Agency committee has recommended that Sarclisa (isatuximab), used in combination with standard-of-care medications, be approved for…